Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
REGULATORY
Japan Approves Novartis’ Fabhalta, Lilly’s Jaypirca, and Lots More
Japan’s Ministry of Health, Labor and Welfare (MHLW) handed out approval for a slew of new medicines and label expansions on June 24, including Novartis Pharma’s Fabhalta (iptacopan) and Eli Lilly’s Jaypirca (pirtobrutinib). The latest batch of products granted the…
To read the full story
Related Article
- Sanofi Releases Typhim Vi, First Typhoid Vaccine in Japan
July 1, 2025
- Japan's First Eylea Biosimilar Wins Nod, Potential Listing in November
June 25, 2024
- Japan Health Ministry Panel Gives Blessing to Novartis’ PNH Drug Iptacopan and More
June 4, 2024
- MHLW Panel OKs Avigan for SFTS with Strings Attached, Shionogi COVID Jab Only for Primary Use
May 27, 2024
- Jaypirca, Prevymis Sail Through MHLW Panel Review; Avigan’s SFTS Use on Hold
May 10, 2024
- Japan’s 1st Eylea Biosimilar Now in Line for Approval, AMD Dropped for Patent Reasons
April 30, 2024
REGULATORY
- Kisunla Price Cut Set at 3.93% under Japan’s CEA Scheme
November 6, 2026
- Japan Nudged to Probe Wide Gaps in Biosimilar Uptake
November 6, 2026
- Japan Eyes Multi-Year Investment Support for Wholesalers in FY2027 Budget
November 6, 2026
- Japan Poised to Broker Generic Firms’ Product Consolidation Talks
November 6, 2026
- Japan Issues Guidance on AI Model Use in Drug Manufacturing, Quality Control
November 6, 2026
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…